The Cancer Immunologic Data Commons (CIDC) is comprised of a team at Dana-Farber Cancer Institute that utilizes a strong track record in infrastructure building and an expertise in bioinformatics methods, imaging, cancer immunology and cancer clinical trials/biomarkers to provide necessary support to the CIMACs. The group also has leveraged many powerful infrastructures already in wide usage, such as the cBioPortal for Cancer Genomics and FireCloud to bolster strategies that ensure the successful execution of the project.
There are seven main goals that the CIDC is responsible for that are essential to the progress of network activities. These include:
- Creation of data standards for all CIMAC assays
- Creation and maintenance of a centralized data repository and coordinated activities for CIMAC data submission to the CIDC
- Development and maintenance of uniform bioinformatics pipelines for standardization of CIMAC data
- Development of shared infrastructure for executing integrative and correlative analysis on all CIMAC data
- Development of data APIs and role-based access
- Development of data visualization tools, enabling CIMAC investigators and external researcher to conduct own analyses
- Coordination within CIMAC-CIDC network logistic and scientific activities for biomarker discovery and validation
Shirley Liu, PhD
Shirley Liu, PhD, is Professor of Biostatistics and Computational Biology at Harvard T.H. Chan School of Public Health and the Co-Director of the Center for Functional Cancer Epigenetics (CFCE) at Dana-Farber Cancer Institute. She has extensive experience in bioinformatics algorithm development and data integration of cancer genomics, including methods for inferring tumor infiltrating immune cells and identifying TCR repertoire from tumor RNA-seq.
Ethan Cerami, PhD
Ethan Cerami, PhD, is the Director of the Knowledge Systems Group and Lead Scientist in the Department of Biostatistics and Computational Biology at Dana-Farber Cancer Institute. His interests focus primarily on understanding the landscape of kinase fusions in cancer, which have had immediate clinical implications and have expanded the therapeutic options for cancer patients.